This is where personalized medicine becomes valuable: understanding your unique genetics and medication response helps you find the right combination of treatments

p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis

These effects are transient, dose-dependent, and tend to improve as the body adjusts to treatment
Learn More Aesthetics & MedSpa Premium aesthetic treatments including Botox, fillers, PDO threads, and laser hair removal
The following individuals may benefit most from these GLP-1 treatments: The compounded liraglutide cost is usually lower than Semaglutide, though prices vary by pharmacy and dosage
[20] [21] Patients with established cardiovascular disease should use ibuprofen with particular caution, at the lowest effective dose, and only after discussion with their healthcare provider